Key result
Ivabradine (10 mg/kg/day) reversed myocardial fibrosis and enhanced restoration of deranged excitation-contraction coupling during mechanical unloading better than metoprolol in a rat model of HF.
Why the study?
Does ivabradine improve structural and functional reverse remodeling during mechanical unloading in a rodent model of heart failure?
Does ivabradine improve structural and functional reverse remodeling during mechanical unloading in a rodent model of heart failure?
Ivabradine reverses myocardial fibrosis and enhances restoration of excitation-contraction coupling during mechanical unloading in a rodent heart failure model, suggesting potential benefits for patients receiving LVAD therapy.
May augment reverse remodeling with mechanical unloading in rodent HF; leaves open translation to LVAD patients.
AIMS: Ivabradine (Iva) has shown beneficial structural and functional effects in clinical and experimental heart failure (HF), but its action in combination with mechanical unloading (MU), such as during treatment with left ventricular assist devices (LVAD), is unknown. The aim of this study was to investigate the effects of Iva during MU, in a rodent model of HF. METHODS AND RESULTS: We studied the chronic effects (4 weeks) of Iva (10 mg/kg/day) alone and in combination with MU [induced by heterotopic abdominal heart transplantation (HATx)] on whole-heart and cellular structure, function, and excitation-contraction (E-C) coupling in a rodent (rat) model of HF, 12 weeks post-left coronary artery (LCA) ligation. Effects of Iva were compared with those of β-blockade using metoprolol [(Met), 250 mg/kg/day]. Iva, but not Met, reversed myocardial fibrosis, alone and in combination with MU. MU-induced restoration of deranged E-C coupling was enhanced by Iva to a greater extent than Met: both Iva and Met enhanced the recovery of the Ca(2+) transient amplitude and the sarcoplasmic reticulum (SR) Ca(2+) content, but Iva alone maintained MU-induced normalization of L-type Ca(2+) current and t-tubule abnormalities. Met prevented MU-induced reduction in the myocardial size (myocardial atrophy); Iva had no effect on this parameter. CONCLUSION: Iva shows beneficial structural and E-C coupling effects during MU: Iva reverses myocardial fibrosis and enhances the restoration of deranged E-C coupling, displaying more beneficial effects than that of Met. These results suggest that Iva may prove effective in enhancing functional recovery in heart failure patients receiving LVAD therapy.
No takes yet. Share an insight, caveat, or question.
Navaratnarajah et al. (2012) studied Heart failure. Ivabradine vs. Metoprolol was evaluated on Whole-heart and cellular structure, function, and excitation-contraction coupling. Ivabradine (10 mg/kg/day) reversed myocardial fibrosis and enhanced restoration of deranged excitation-contraction coupling during mechanical unloading better than metoprolol in a rat model of HF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: